OncoSec Medical Inc (ONCSQ)

[chickpea598]

I just received a response from investor relations regarding my question as to whether or not the Biomarker assay was used in the study/data released at AACR earlier this year. Here is their response:


The biomarker assay was not used with patients in the study/data that was presented at the Annual AACR Meeting in April. These patients were enrolled in our Phase II melanoma monotherapy study. After completion of our study, some patients went on to receive anti-PD-1 therapy. Researchers documented and analyzed long-term follow-up data after they received anti-PD-1 treatment.

The biomarker assay is currently being used to select patients for the ongoing Phase II clinical trial evaluating the combination of OncoSec's ImmunoPulse IL-12 and pembrolizumab in melanoma patients. We're using the assay's ability to select patients, who are unlikely to respond to anti-PD-1, and enroll these patients in our Phase II combination trial. Data from this trial is expected to be presented in 2016.